ASX:NEUPharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) Reports Higher Sales And Interim Dividend, Is The Valuation Too Rich?
Why Neuren Pharmaceuticals stock is in focus now
Neuren Pharmaceuticals (ASX:NEU) has caught investor attention after reporting half year 2026 results showing higher sales and revenue, a lower net profit figure, and the declaration of a fully franked interim dividend.
Neuren Pharmaceuticals shares trade at A$19.89, with a 90 day share price return of 46.36% and a 30 day share price return of 10.50%. This comes despite a 7 day share price pullback of 11.72%, while the 5 year total shareholder...